Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Detailed price information for C4 Therapeutics Inc (CCCC-Q) from The Globe and Mail including charting and trades.

Biogen Inc. ( (BIIB)) has realeased its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is a leading biotechnology company that specializes ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...